# NetApp, Inc.: financial statements, quarterly NTAP · Nasdaq · CIK 1002047 · [Technology](/sectors/technology.md) · fiscal year ends Apr 24 Pages: [Overview](/companies/ntap.md) · [Financials](/companies/ntap/financials.md) · [Filings](/companies/ntap/filings.md) · [Insiders](/companies/ntap/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ntap/financials.md?period=annual). ## Income statement | Line item | Unit | Q2 FY2024 (2023-10-27) | Q3 FY2024 (2024-01-26) | Q4 FY2024 (2024-04-26) | Q1 FY2025 (2024-07-26) | Q2 FY2025 (2024-10-25) | Q3 FY2025 (2025-01-24) | Q4 FY2025 (2025-04-25) | Q1 FY2026 (2025-07-25) | Q2 FY2026 (2025-10-24) | Q3 FY2026 (2026-01-23) | Q4 FY2026 (2026-04-24) | Q1 FY2027 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1,562](/filings/0000950170-24-130551.md) | [1,606](/filings/0000950170-25-029066.md) | [1,668 d](/filings/0001193125-26-259683.md) | [1,541](/filings/0001193125-25-189700.md) | [1,658](/filings/0001193125-25-297237.md) | [1,641](/filings/0001193125-26-076622.md) | [1,732 d](/filings/0001193125-26-259683.md) | [1,559](/filings/0001193125-26-380207.md) | [1,705](/filings/0001193125-25-297237.md) | [1,713](/filings/0001193125-26-076622.md) | [1,948 d](/filings/0001193125-26-259683.md) | [2,025](/filings/0001193125-26-380207.md) | | Cost of revenue | $m | [452](/filings/0000950170-24-130551.md) | [455](/filings/0000950170-25-029066.md) | [492 d](/filings/0001193125-26-259683.md) | [443](/filings/0001193125-25-189700.md) | [481](/filings/0001193125-25-297237.md) | [496](/filings/0001193125-26-076622.md) | [539 d](/filings/0001193125-26-259683.md) | [461](/filings/0001193125-26-380207.md) | [478](/filings/0001193125-25-297237.md) | [504](/filings/0001193125-26-076622.md) | [583 d](/filings/0001193125-26-259683.md) | [606](/filings/0001193125-26-380207.md) | | Gross profit | $m | [1,110](/filings/0000950170-24-130551.md) | [1,151](/filings/0000950170-25-029066.md) | [1,176 d](/filings/0001193125-26-259683.md) | [1,098](/filings/0001193125-25-189700.md) | [1,177](/filings/0001193125-25-297237.md) | [1,145](/filings/0001193125-26-076622.md) | [1,193 d](/filings/0001193125-26-259683.md) | [1,098](/filings/0001193125-26-380207.md) | [1,227](/filings/0001193125-25-297237.md) | [1,209](/filings/0001193125-26-076622.md) | [1,365 d](/filings/0001193125-26-259683.md) | [1,419](/filings/0001193125-26-380207.md) | | Research and development | $m | [262](/filings/0000950170-24-130551.md) | [249](/filings/0000950170-25-029066.md) | [271 d](/filings/0001193125-26-259683.md) | [252](/filings/0001193125-25-189700.md) | [257](/filings/0001193125-25-297237.md) | [247](/filings/0001193125-26-076622.md) | [256 d](/filings/0001193125-26-259683.md) | [242](/filings/0001193125-26-380207.md) | [251](/filings/0001193125-25-297237.md) | [237](/filings/0001193125-26-076622.md) | [261 d](/filings/0001193125-26-259683.md) | [274](/filings/0001193125-26-380207.md) | | Operating income | $m | [304](/filings/0000950170-24-130551.md) | [366](/filings/0000950170-25-029066.md) | [366 d](/filings/0001193125-26-259683.md) | [282](/filings/0001193125-25-189700.md) | [345](/filings/0001193125-25-297237.md) | [362](/filings/0001193125-26-076622.md) | [348 d](/filings/0001193125-26-259683.md) | [309](/filings/0001193125-26-380207.md) | [399](/filings/0001193125-25-297237.md) | [434](/filings/0001193125-26-076622.md) | [532 d](/filings/0001193125-26-259683.md) | [484](/filings/0001193125-26-380207.md) | | Interest expense | $m | [15.0](/filings/0000950170-23-067033.md) | [17.0](/filings/0000950170-24-023115.md) | [16.0 d](/filings/0000950170-24-071327.md) | [16.0](/filings/0001193125-25-189700.md) | [15.0](/filings/0001193125-25-297237.md) | [12.0](/filings/0001193125-26-076622.md) | [21.0 d](/filings/0001193125-26-259683.md) | [29.0](/filings/0001193125-25-189700.md) | [26.0](/filings/0001193125-25-297237.md) | [26.0](/filings/0001193125-26-076622.md) | [28.0 d](/filings/0001193125-26-259683.md) | not reported | | Income tax | $m | [82.0](/filings/0000950170-24-130551.md) | [69.0](/filings/0000950170-25-029066.md) | [89.0 d](/filings/0001193125-26-259683.md) | [51.0](/filings/0001193125-25-189700.md) | [61.0](/filings/0001193125-25-297237.md) | [71.0](/filings/0001193125-26-076622.md) | [14.0 d](/filings/0001193125-26-259683.md) | [71.0](/filings/0001193125-26-380207.md) | [88.0](/filings/0001193125-25-297237.md) | [99.0](/filings/0001193125-26-076622.md) | [114 d](/filings/0001193125-26-259683.md) | [109](/filings/0001193125-26-380207.md) | | Net income | $m | [233](/filings/0000950170-24-130551.md) | [313](/filings/0000950170-25-029066.md) | [291 d](/filings/0001193125-26-259683.md) | [248](/filings/0001193125-25-189700.md) | [299](/filings/0001193125-25-297237.md) | [299](/filings/0001193125-26-076622.md) | [340 d](/filings/0001193125-26-259683.md) | [233](/filings/0001193125-26-380207.md) | [305](/filings/0001193125-25-297237.md) | [334](/filings/0001193125-26-076622.md) | [404 d](/filings/0001193125-26-259683.md) | [375](/filings/0001193125-26-380207.md) | | Diluted EPS | $ per share | [1.10](/filings/0000950170-24-130551.md) | [1.48](/filings/0000950170-25-029066.md) | not reported | [1.17](/filings/0001193125-25-189700.md) | [1.42](/filings/0001193125-25-297237.md) | [1.44](/filings/0001193125-26-076622.md) | not reported | [1.15](/filings/0001193125-26-380207.md) | [1.51](/filings/0001193125-25-297237.md) | [1.67](/filings/0001193125-26-076622.md) | not reported | [1.88](/filings/0001193125-26-380207.md) | | Basic EPS | $ per share | [1.12](/filings/0000950170-24-130551.md) | [1.52](/filings/0000950170-25-029066.md) | not reported | [1.20](/filings/0001193125-25-189700.md) | [1.47](/filings/0001193125-25-297237.md) | [1.47](/filings/0001193125-26-076622.md) | not reported | [1.16](/filings/0001193125-26-380207.md) | [1.53](/filings/0001193125-25-297237.md) | [1.69](/filings/0001193125-26-076622.md) | not reported | [1.91](/filings/0001193125-26-380207.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q2 FY2024 (2023-10-27) | Q3 FY2024 (2024-01-26) | FY2024 (2024-04-26) | Q1 FY2025 (2024-07-26) | Q2 FY2025 (2024-10-25) | Q3 FY2025 (2025-01-24) | FY2025 (2025-04-25) | Q1 FY2026 (2025-07-25) | Q2 FY2026 (2025-10-24) | Q3 FY2026 (2026-01-23) | FY2026 (2026-04-24) | Q1 FY2027 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $bn | [1.9](/filings/0000950170-23-067033.md) | [1.8](/filings/0000950170-24-023115.md) | [1.9](/filings/0000950170-25-083705.md) | [1.7](/filings/0000950170-24-101408.md) | [1.5](/filings/0000950170-24-130551.md) | [1.5](/filings/0000950170-25-029066.md) | [2.7](/filings/0001193125-26-259683.md) | [2.1](/filings/0001193125-25-189700.md) | [2.1](/filings/0001193125-25-297237.md) | [1.6](/filings/0001193125-26-076622.md) | [2.1](/filings/0001193125-26-380207.md) | [1.6](/filings/0001193125-26-380207.md) | | Current assets | $bn | [4.0](/filings/0000950170-23-067033.md) | [4.3](/filings/0000950170-24-023115.md) | [4.9](/filings/0000950170-25-083705.md) | [4.3](/filings/0000950170-24-101408.md) | [3.9](/filings/0000950170-24-130551.md) | [3.9](/filings/0000950170-25-029066.md) | [5.9](/filings/0001193125-26-259683.md) | [4.7](/filings/0001193125-25-189700.md) | [4.7](/filings/0001193125-25-297237.md) | [5.0](/filings/0001193125-26-076622.md) | [5.8](/filings/0001193125-26-380207.md) | [5.7](/filings/0001193125-26-380207.md) | | Total assets | $bn | [9.1](/filings/0000950170-23-067033.md) | [9.4](/filings/0000950170-24-023115.md) | [9.9](/filings/0000950170-25-083705.md) | [9.3](/filings/0000950170-24-101408.md) | [9.0](/filings/0000950170-24-130551.md) | [9.0](/filings/0000950170-25-029066.md) | [10.8](/filings/0001193125-26-259683.md) | [9.7](/filings/0001193125-25-189700.md) | [9.6](/filings/0001193125-25-297237.md) | [10.0](/filings/0001193125-26-076622.md) | [10.7](/filings/0001193125-26-380207.md) | [11.0](/filings/0001193125-26-380207.md) | | Current liabilities | $bn | [3.7](/filings/0000950170-23-067033.md) | [3.8](/filings/0000950170-24-023115.md) | [4.1](/filings/0000950170-25-083705.md) | [4.5](/filings/0000950170-24-101408.md) | [4.3](/filings/0000950170-24-130551.md) | [4.2](/filings/0000950170-25-029066.md) | [4.7](/filings/0001193125-26-259683.md) | [3.6](/filings/0001193125-25-189700.md) | [3.5](/filings/0001193125-25-297237.md) | [3.6](/filings/0001193125-26-076622.md) | [4.0](/filings/0001193125-26-380207.md) | [4.6](/filings/0001193125-26-380207.md) | | Total liabilities | $bn | [8.3](/filings/0000950170-23-067033.md) | [8.4](/filings/0000950170-24-023115.md) | [8.7](/filings/0000950170-25-083705.md) | [8.4](/filings/0000950170-24-101408.md) | [8.1](/filings/0000950170-24-130551.md) | [8.0](/filings/0000950170-25-029066.md) | [9.8](/filings/0001193125-26-259683.md) | [8.7](/filings/0001193125-25-189700.md) | [8.6](/filings/0001193125-25-297237.md) | [8.8](/filings/0001193125-26-076622.md) | [9.4](/filings/0001193125-26-380207.md) | [9.5](/filings/0001193125-26-380207.md) | | Long-term debt | $bn | [2.0](/filings/0000950170-23-067033.md) | [2.0](/filings/0000950170-24-023115.md) | [2.0](/filings/0000950170-25-083705.md) | [1.2](/filings/0000950170-24-101408.md) | [1.2](/filings/0000950170-24-130551.md) | [1.2](/filings/0000950170-25-029066.md) | [2.5](/filings/0001193125-26-259683.md) | [2.5](/filings/0001193125-25-189700.md) | [2.5](/filings/0001193125-25-297237.md) | [2.5](/filings/0001193125-26-076622.md) | [2.5](/filings/0001193125-26-380207.md) | [1.9](/filings/0001193125-26-380207.md) | | Current portion of debt | $bn | [0.4](/filings/0000950170-23-067033.md) | [0.4](/filings/0000950170-24-023115.md) | [0.4](/filings/0000950170-25-083705.md) | [1.1](/filings/0000950170-24-101408.md) | [0.7](/filings/0000950170-24-130551.md) | [0.8](/filings/0000950170-25-029066.md) | [0.8](/filings/0001193125-26-259683.md) | [0.0](/filings/0001193125-25-189700.md) | [0.0](/filings/0001193125-25-297237.md) | [0.0](/filings/0001193125-26-076622.md) | [0.0](/filings/0001193125-26-380207.md) | [0.6](/filings/0001193125-26-380207.md) | | Short-term borrowings | $bn | [0.0](/filings/0000950170-23-067033.md) | [0.0](/filings/0000950170-24-023115.md) | [0.0](/filings/0000950170-25-083705.md) | [0.0](/filings/0000950170-24-101408.md) | [0.0](/filings/0000950170-24-130551.md) | [0.0](/filings/0000950170-25-029066.md) | [0.0](/filings/0001193125-26-259683.md) | [0.0](/filings/0001193125-25-189700.md) | [0.0](/filings/0001193125-25-297237.md) | [0.0](/filings/0001193125-26-076622.md) | [0.0](/filings/0001193125-26-380207.md) | [0.0](/filings/0001193125-26-380207.md) | | Shareholders' equity | $bn | [0.8](/filings/0000950170-25-029066.md) | [1.0](/filings/0000950170-25-029066.md) | [1.1](/filings/0001193125-26-259683.md) | [0.9](/filings/0001193125-25-297237.md) | [0.9](/filings/0001193125-26-076622.md) | [1.0](/filings/0001193125-26-076622.md) | [1.0](/filings/0001193125-26-380207.md) | [1.0](/filings/0001193125-26-380207.md) | [1.0](/filings/0001193125-26-076622.md) | [1.2](/filings/0001193125-26-076622.md) | [1.4](/filings/0001193125-26-380207.md) | [1.5](/filings/0001193125-26-380207.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Short-term borrowings: us-gaap:CommercialPaper - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q2 FY2024 (2023-10-27) | Q3 FY2024 (2024-01-26) | Q4 FY2024 (2024-04-26) | Q1 FY2025 (2024-07-26) | Q2 FY2025 (2024-10-25) | Q3 FY2025 (2025-01-24) | Q4 FY2025 (2025-04-25) | Q1 FY2026 (2025-07-25) | Q2 FY2026 (2025-10-24) | Q3 FY2026 (2026-01-23) | Q4 FY2026 (2026-04-24) | Q1 FY2027 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [135 d](/filings/0000950170-24-130551.md) | [484 d](/filings/0000950170-25-029066.md) | [613 d](/filings/0001193125-26-259683.md) | [341](/filings/0001193125-25-189700.md) | [105 d](/filings/0001193125-25-297237.md) | [385 d](/filings/0001193125-26-076622.md) | [675 d](/filings/0001193125-26-259683.md) | [673](/filings/0001193125-26-380207.md) | [127 d](/filings/0001193125-25-297237.md) | [317 d](/filings/0001193125-26-076622.md) | [950 d](/filings/0001193125-26-259683.md) | [503](/filings/0001193125-26-380207.md) | | Capital expenditure | $m | [38.0 d](/filings/0000950170-24-130551.md) | [36.0 d](/filings/0000950170-25-029066.md) | [46.0 d](/filings/0001193125-26-259683.md) | [41.0](/filings/0001193125-25-189700.md) | [45.0 d](/filings/0001193125-25-297237.md) | [47.0 d](/filings/0001193125-26-076622.md) | [35.0 d](/filings/0001193125-26-259683.md) | [53.0](/filings/0001193125-26-380207.md) | [49.0 d](/filings/0001193125-25-297237.md) | [46.0 d](/filings/0001193125-26-076622.md) | [50.0 d](/filings/0001193125-26-259683.md) | [102](/filings/0001193125-26-380207.md) | | Dividends paid | $m | [103 d](/filings/0000950170-24-130551.md) | [103 d](/filings/0000950170-25-029066.md) | [104 d](/filings/0001193125-26-259683.md) | [107](/filings/0001193125-25-189700.md) | [106 d](/filings/0001193125-25-297237.md) | [106 d](/filings/0001193125-26-076622.md) | [105 d](/filings/0001193125-26-259683.md) | [104](/filings/0001193125-26-380207.md) | [103 d](/filings/0001193125-25-297237.md) | [103 d](/filings/0001193125-26-076622.md) | [103 d](/filings/0001193125-26-259683.md) | [102](/filings/0001193125-26-380207.md) | | Share repurchases | $m | [300 d](/filings/0000950170-24-130551.md) | [100 d](/filings/0000950170-25-029066.md) | [100 d](/filings/0001193125-26-259683.md) | [400](/filings/0001193125-25-189700.md) | [300 d](/filings/0001193125-25-297237.md) | [200 d](/filings/0001193125-26-076622.md) | [250 d](/filings/0001193125-26-259683.md) | [300](/filings/0001193125-26-380207.md) | [250 d](/filings/0001193125-25-297237.md) | [200 d](/filings/0001193125-26-076622.md) | [200 d](/filings/0001193125-26-259683.md) | [200](/filings/0001193125-26-380207.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividends - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q2 FY2023 (2022-10-28) | Q3 FY2023 (2023-01-27) | Q1 FY2024 (2023-07-28) | Q2 FY2024 (2023-10-27) | Q3 FY2024 (2024-01-26) | Q1 FY2025 (2024-07-26) | Q2 FY2025 (2024-10-25) | Q3 FY2025 (2025-01-24) | Q1 FY2026 (2025-07-25) | Q2 FY2026 (2025-10-24) | Q3 FY2026 (2026-01-23) | Q1 FY2027 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [220](/filings/0000950170-23-067033.md) | [219](/filings/0000950170-24-023115.md) | [216](/filings/0000950170-24-101408.md) | [211](/filings/0000950170-24-130551.md) | [211](/filings/0000950170-25-029066.md) | [212](/filings/0001193125-25-189700.md) | [210](/filings/0001193125-25-297237.md) | [208](/filings/0001193125-26-076622.md) | [203](/filings/0001193125-26-380207.md) | [202](/filings/0001193125-25-297237.md) | [200](/filings/0001193125-26-076622.md) | [200](/filings/0001193125-26-380207.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 196,419,005 at 2026-08-28, from the cover of the [10-Q filed 2026-09-02](/filings/0001193125-26-380207.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.